Colchicine, a widely available gout medication, has received FDA approval to be used in low dose to prevent cardiovascular events in patients with proven coronary disease. The approval to use low dose ...

Colchicine may be used with caution to manage flare-ups of crystal-induced arthritis among patients with severe chronic kidney disease, with dosage modifications and careful monitoring required.

Scilex Holding Company announced the publication of important dosing adjustments for GLOPERBA®, its liquid oral colchicine product for gout management, in a peer-reviewed journal. GLOPERBA® is unique ...

Please provide your email address to receive an email when new articles are posted on . Patients with elevated levels of high-sensitivity C-reactive protein are at risk for CV events. Low-dose ...

Can you explain the recent confusion surrounding the generic availability of colchicine? Why is there only 1 brand of colchicine product available? It is also important to note that colchicine often ...

BASEL, Switzerland—Low-dose colchicine doesn’t significantly reduce MACE in patients who have had a nonsevere ischemic stroke or high-risk TIA, according to the results of the CONVINCE trial. Through ...

While conducting the CLEAR SYNERGY (OASIS 9) trial, lead author Sanjit Jolly, MD continued to treat some of his patients post–myocardial infarction (MI), including his late father, with colchicine.